Equities Analysts Issue Forecasts for Indivior Q4 Earnings

Indivior PLC (NASDAQ:INDV) – Analysts at Northland Securities dropped their Q4 2026 earnings estimates for Indivior in a report issued on Thursday, February 26th. Northland Securities analyst C. Byrnes now expects that the company will earn $0.70 per share for the quarter, down from their prior forecast of $0.71. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

Other equities research analysts also recently issued reports about the company. Morgan Stanley restated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Finally, HC Wainwright increased their price target on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Indivior presently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Indivior Price Performance

Shares of INDV opened at $32.72 on Monday. The firm has a market capitalization of $4.09 billion, a P/E ratio of 19.95 and a beta of 0.83. Indivior has a one year low of $8.34 and a one year high of $38.00. The business has a fifty day moving average of $34.55 and a 200 day moving average of $30.09.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. The business had revenue of $358.00 million during the quarter, compared to analyst estimates of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%.

Insider Activity

In other news, Director David E. Wheadon bought 1,771 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the purchase, the director owned 14,395 shares in the company, valued at $509,439.05. This represents a 14.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Daniel A. Ninivaggi bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 16,923 shares in the company, valued at $598,904.97. This trade represents a 4.80% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 4,871 shares of company stock worth $172,385.

Institutional Investors Weigh In On Indivior

Large investors have recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Indivior during the 2nd quarter worth approximately $855,000. Federated Hermes Inc. purchased a new position in shares of Indivior in the third quarter valued at $8,120,000. Aberdeen Group plc bought a new stake in Indivior in the third quarter worth $3,875,000. Pacer Advisors Inc. purchased a new stake in Indivior during the third quarter valued at $9,086,000. Finally, Acadian Asset Management LLC lifted its position in Indivior by 124.4% during the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock valued at $21,977,000 after purchasing an additional 827,230 shares during the last quarter. 60.33% of the stock is owned by institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.